MIRM
Mirum Pharmaceuticals Inc
79.30$
-2.7%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
Mirum Pharmaceuticals Inc (MIRM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -273 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.4 | -0.5 | -2.4 | -8.0 | -15 | -14 | -18 | -17 | -17 | -36 | -25 | -40 | -34 | -33 | -40 | -20 | -26 | -34 | -19 | -17 | -18 | -17 | 15 | -3.8 | 4.0 | -5.1 | -2.0 | 12 | 40 | 6.1 | -229 | -273 | -456 | |
| 0.0 | – | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.4 | 0.7 | 1.1 | 1.3 | 1.3 | 1.3 | 2.7 | 5.5 | 5.7 | 5.9 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.9 | 14 | 33 | |
| – | 0.1 | 0.2 | 1.6 | 2.1 | 2.1 | 2.6 | 3.0 | 3.4 | 3.6 | 5.3 | 4.8 | 7.4 | 5.6 | 6.6 | 6.8 | 6.7 | 6.9 | 8.6 | 8.4 | 8.4 | 9.7 | 11 | 12 | 12 | 13 | 16 | 18 | 18 | 19 | 36 | 67 | 140 | |
| 0.2 | – | 0.2 | 1.6 | 2.0 | 1.9 | 2.5 | 3.0 | 3.5 | 4.0 | 5.3 | 11 | 7.4 | 5.6 | 6.6 | 6.8 | 6.7 | 6.9 | 8.6 | 57 | 7.8 | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0 | 3.3 | 3.8 | -2.2 | 2.2 | 0.3 | 3.1 | 0.4 | -3.2 | 17 | -7.3 | 1.1 | 6.4 | -14 | 3.5 | -1.8 | -9.0 | -2.6 | -3.5 | -5.6 | -11 | 24 | 1.6 | -1.2 | -1.7 | -11 | -6.6 | 12 | -14 | 102 | 62 | 162 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19 | 0.0 | 0.0 | 0.0 | 0.2 | 15 | 0.1 | 0.0 | 5.0 | 0.0 | 11 | 10 | 0.0 | 0.0 | 0.1 | 0.2 | 0.6 | 0.7 | 0.7 | 2.1 | |
| 0.0 | -11 | 0.0 | -58 | -64 | -5.1 | 34 | 28 | -19 | -4.9 | -33 | -24 | -2.2 | 108 | 37 | 24 | -80 | 27 | 27 | 51 | -183 | -2.0 | 0.0 | -73 | -18 | 0.6 | -16 | -6.6 | -2.2 | 1.0 | -12 | -172 | -184 | |
| – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.0 | 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | |
| – | – | 0.0 | 60 | 127 | 127 | 45 | – | – | – | 7.0 | 0.9 | 0.3 | 0.7 | 19 | 6.3 | 88 | 16 | 16 | 2.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 305 | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| 59 | 90 | 0.0 | 59 | 68 | 0.0 | 45 | 0.0 | 2.1 | 135 | 6.6 | 66 | 0.3 | 0.6 | 18 | 5.2 | 86 | -0.3 | 13 | 115 | 207 | 1.8 | 1.2 | 7.3 | 3.9 | 5.3 | 6.4 | 8.7 | 16 | 9.0 | 270 | 482 | 777 | |
| -2.5 | 78 | -2.5 | -7.7 | -11 | -19 | 60 | 11 | -34 | 93 | -51 | 1.3 | -36 | 75 | 15 | 9.0 | -20 | -7.8 | 21 | 148 | 5.8 | -17 | 17 | -69 | -10 | -0.5 | -11 | 16 | 54 | 16 | 28 | 34 | 132 | |
| – | -0.5 | -2.5 | -8.0 | -15 | -14 | -18 | -17 | -17 | -36 | -25 | -40 | -34 | -52 | -40 | -20 | -26 | -35 | -34 | -17 | -18 | -22 | 15 | -15 | -6.2 | -5.1 | -2.0 | 12 | 39 | 5.5 | -229 | -274 | -458 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.